| Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co.'s development plan for STS101 included a completed Phase 1 trial; a Phase 3 efficacy trial (the SUMMIT trial), which is ongoing; and continuation of the open-label, Phase 3 long-term safety trial of STS101 (the ASCEND trial). The STSA average annual return since 2019 is shown above.
The Average Annual Return on the STSA average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether STSA average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the STSA average annual return calculation with any dividends reinvested as applicable (on ex-dates).